Title
Category
Credits
Event date
Cost
Newer Approaches to Treatment of Bladder Cancer
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.
Management of Immune Checkpoint Inhibitor-Related Toxicities
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The role of metastasis-directed therapy (MDT) for patients with oligometastatic cancer is rapidly evolving, and trials have shown that integrating metastasis-directed therapy into the care of these patients can improve oncologic outcomes including time to disease progression and overall survival.
Smoking Cessation for Patients with Cancer: State of the Evidence
  • Smoking Cessation
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Smoking is not only linked to the development of tobacco-related cancers, but also to the prognosis upon diagnosis and risk of death during treatment. Clinicians must understand the complexity of smoking cessation interventions in this patient population to mitigate smoking-associated risks and improve patient outcomes.
Updates to Management of Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Best Practices for Oncology Urgent Care
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Oncology urgent care is an emerging area of interest requiring many clinical and practical considerations for implementation. Education is needed on the value of offering oncology urgent care and the factors that lead to successful programs.
Expansion of Recommendations for Hereditary Cancers
  • Genetic/Familial High-Risk Assessment
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Team-Based Case Review: Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Additionally, clinical approach for all uncommon histologies of ovarian cancer including rare malignant germ cell tumors can be variable.
Advances in Head and Neck Cancers: Nasopharyngeal and Oral Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing and preventing sequelae following surgery, radiation therapy (RT), and systemic therapy (e.g., trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, renal failure) requires professionals familiar with head and neck cancers. Limited data are available comparing the efficacy of different chemoradiotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN). Immunotherapy options for recurrent/metastatic nasopharyngeal cancer is a rapidly evolving area of research.

Pages